MRK logo

Merck KGaA Stock Price

XTRA:MRK Community·€47.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 76 Fair Values set on narratives written by author

MRK Share Price Performance

€109.45
-24.95 (-18.56%)
€143.88
Fair Value
€109.45
-24.95 (-18.56%)
23.9% undervalued intrinsic discount
€143.88
Fair Value
Price €109.45
AnalystConsensusTarget €143.88
AnalystLowTarget €127.00
AnalystHighTarget €187.48

MRK Community Narratives

AnalystConsensusTarget·
Fair Value €143.88 23.9% undervalued intrinsic discount

MRK: Future CEO Appointment Will Support Recovery and Restore Confidence

0users have liked this narrative
0users have commented on this narrative
51users have followed this narrative
AnalystLowTarget·
Fair Value €127 13.8% undervalued intrinsic discount

Legacy Pharmaceutical And Chemical Businesses Will Decline As Regulations Tighten

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AnalystHighTarget·
Fair Value €187.48 41.6% undervalued intrinsic discount

Aging Populations And Digitalization Will Unlock Life Sciences Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
€127
13.8% undervalued intrinsic discount
Revenue
1.73% p.a.
Profit Margin
13.94%
Future PE
20.59x
Price in 2029
€146.63

Trending Discussion

Updated Narratives

MRK logo

MRK: Margin Resilience And New TGCT Therapy Will Shape Future Upside

Fair Value: €187.48 41.6% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MRK logo

MRK: Mixed Rating Shifts Will Shape Perceived Balance Of Future Return Potential

Fair Value: €127 13.8% undervalued intrinsic discount
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MRK logo

MRK: Margin Strength And AI Deal Will Drive Future Upside

Fair Value: €143.88 23.9% undervalued intrinsic discount
51 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with excellent balance sheet and pays a dividend.

0 Risks
5 Rewards

Merck KGaA Key Details

€21.1b

Revenue

€8.7b

Cost of Revenue

€12.4b

Gross Profit

€9.8b

Other Expenses

€2.6b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 13, 2026
6.00
58.90%
12.36%
39.5%
View Full Analysis

About MRK

Founded
1668
Employees
59077
CEO
Belen Garijo Lopez
WebsiteView website
www.emdgroup.com

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck KG.

Recent MRK News & Updates

Recent updates

No updates